US Biotech Leaders Launch Alliance to Defend Innovation Edge

WASHINGTON, DC – May 05, 2026 – A coalition of prominent U.S. biotechnology leaders has launched a new national alliance, warning that America's long-held supremacy in medical innovation is facing unprecedented pressure. The American Biotech Innovation Alliance (ABIA) debuted today with 21 founding member companies, announcing a singular mission: to forge a cohesive national strategy to sustain and extend the country's leadership in the global biotech race.

The launch comes at what organizers describe as a critical "strategic inflection point" for an industry responsible for some of the world's most significant health breakthroughs. The alliance, structured as a 501(c)(6) organization, brings together a diverse cross-section of the industry, from preclinical startups to commercial-stage firms, representing both established and emerging innovation hubs across the nation.

“We’ve spent decades building the world’s leading biotech ecosystem but we’re now operating in a very different environment,” said Patroski Lawson, Founder of ABIA, in a statement accompanying the launch. “If we don’t start thinking more strategically about what comes next, we risk losing ground."

A Response to Mounting Pressure

The formation of ABIA is a direct response to a convergence of challenges that industry leaders believe threaten to erode the U.S. advantage. For decades, the nation has been the undisputed global center for translating scientific discovery into life-saving therapies and billion-dollar companies. However, that dominance is no longer guaranteed.

According to the alliance, this once-unassailable position is now being challenged by several factors. Increasing global competition is a primary concern, as other nations, particularly in Asia and Europe, are making strategic, government-backed investments to build their own domestic biotech sectors, aggressively seeking to attract top talent, capital, and advanced manufacturing capabilities.

Domestically, the landscape is also shifting. The alliance points to volatility in capital markets, which has made fundraising more difficult for early and mid-stage companies that are years away from profitability. This financial uncertainty is compounded by what some see as growing regulatory complexity and a perceived decline in the rate of public investment in fundamental scientific research, the very bedrock of biotech innovation. These pressures combined create a challenging environment for the high-risk, long-term development cycles inherent to biotechnology. The era of passive leadership, the group contends, must be replaced by one of active, coordinated strategy.

A New Model: Beyond Traditional Advocacy

While the U.S. biotech sector is represented by several powerful organizations, ABIA’s founders are clear that their model is intentionally different. Unlike traditional industry groups that focus on broad advocacy and government lobbying on behalf of hundreds of members, ABIA is designed as a focused platform for high-level strategic alignment.

"ABIA is not designed to represent the industry, it is designed to help define where the industry needs to go next," the organization stated.

Its approach centers on convening a smaller, more curated group of leaders for sustained, candid dialogue. The goal is to move beyond fragmented conversations and develop a cohesive, forward-looking framework for the entire U.S. ecosystem. This model prioritizes deep collaboration over broad consensus, aiming to produce actionable strategies rather than reactive policy positions.

“Sustaining leadership and scientific advancements requires continuous prioritization, focus and alignment, capital, and policy advances that set a pace globally,” noted Sheila Frame, President and Head of U.S. Business at Gamida-Cell Inc., a founding member. “ABIA creates a forum to step back, take a longer-term view, and help shape a more coordinated path forward.” This distinction is crucial, positioning the alliance as a strategic think tank for the industry's future rather than another voice in the daily political fray of Washington.

Embracing a Distributed National Ecosystem

The alliance also reflects a fundamental shift in the geography of American innovation. For years, "biotech" was synonymous with a few coastal hubs, primarily Boston/Cambridge and the San Francisco Bay Area. Today, the industry is increasingly a national, distributed network of excellence.

ABIA’s founding membership intentionally incorporates this reality, with leaders from emerging centers of innovation in states like Florida, New Mexico, Texas, and across the Mid-Atlantic. This structure is designed to ensure that a national strategy is not dictated solely by the perspectives of the traditional power centers, but includes the voices and unique challenges of a geographically diverse industry.

“From New Mexico, we’re seeing firsthand how innovation is expanding beyond traditional biotech centers,” said Casey Perkins, Vice President of Corporate Strategy and Business Development at Mercury Bio. “What’s been missing is a cohesive national strategy to connect these emerging ecosystems and ensure they can scale and compete. ABIA creates a platform to bring those perspectives into a broader, more coordinated vision for the future of the industry.”

This inclusive approach is echoed by other members. “Innovation in biotechnology is no longer confined to a handful of traditional hubs,” added David Moss, CEO of INmune Bio. He emphasized the importance of “bringing together voices from across the U.S. ecosystem to help shape a more inclusive and forward-looking strategy for the field.”

Charting a Course for American Innovation

Over the next year, ABIA will embark on its primary mission: the development of a comprehensive national biotech innovation strategy. This will be achieved through a series of curated gatherings and working sessions held across the country, tapping into the collective intelligence of leaders in biotechnology, investment, academia, and policy.

The insights generated from these convenings will culminate in a flagship report. This document is intended to serve as a vital resource, outlining the specific policy, investment, and structural priorities required to secure U.S. leadership for the next generation. Key areas of focus will include optimizing regulatory policy to support innovation while ensuring safety, fostering new models for capital formation, bolstering domestic advanced manufacturing capacity to reduce reliance on foreign supply chains, and developing a robust talent pipeline for the future workforce.

The alliance's work is built on a simple but powerful premise articulated in its launch materials: The future of biotechnology will not be determined by scientific breakthroughs alone. It will be shaped by how effectively the entire innovation ecosystem—from the lab to the capital markets to the halls of government—can align around a shared vision and purpose. ABIA's success will be measured by its ability to forge that alignment and turn strategic dialogue into a durable advantage for the nation.